CHILDRENS HOSPITAL CORPORATION
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $161.4M
- Transactions
- 5,671
- Companies
- 40
- Average per transaction
- $28,461
Who reported the payments
| Takeda Pharmaceuticals U.S.A., Inc. | $44,403,390 |
| Pfizer | $13,077,099 |
| E.r. Squibb & Sons, L.L.C. | $12,124,477 |
| Novartis | $10,030,622 |
| Vertex | $7,934,379 |
| Biogen | $3,912,093 |
| Shire North American Group Inc | $3,800,404 |
| Sarepta Therapeutics, Inc. | $3,730,095 |
| Fresenius Kabi USA, LLC | $3,241,403 |
| Biomarin Pharmaceutical Inc. | $2,843,411 |
| Miach Orthopaedics, Inc. | $2,722,138 |
| Agios Pharmaceuticals, Inc. | $2,667,171 |
| Regeneron | $2,503,969 |
| Sanofi US Services Inc. | $2,273,072 |
| AbbVie | $2,267,296 |
| Ultragenyx Pharmaceutical Inc. | $2,228,616 |
| Bristol Myers Squibb | $2,095,629 |
| Sanofi | $1,999,260 |
| Clinigen, Inc. | $1,707,692 |
| PTC Therapeutics, Inc. | $1,699,827 |
| Genentech, Inc. | $1,690,452 |
| Myriad Genetic Laboratories, Inc. | $1,498,766 |
| Eli Lilly | $1,481,167 |
| Astellas Pharma Inc | $1,433,628 |
| Merck | $1,296,688 |
| Hoffmann-la Roche Limited | $1,088,934 |
| BD | $1,080,534 |
| Acadia Pharmaceuticals Inc | $1,075,320 |
| AstraZeneca | $1,025,785 |
| Adaptive Biotechnologies Corporation | $1,011,212 |
| Genetix Biotherapeutics Inc | $966,145 |
| National Marrow Donor Program | $924,089 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $895,189 |
| Edwards Lifesciences | $801,856 |
| Sanofi-aventis U.S. LLC | $762,358 |
| Janssen Research & Development, LLC | $749,364 |
| F. Hoffmann-la Roche AG | $700,513 |
| Gilead | $688,685 |
| Beigene, Ltd. | $679,026 |
| GE HealthCare | $642,966 |